




Chinese Pharmaceutical Association
Institute of Materia Medica, Chinese Academy of Medical Sciences

Acta Pharmaceutica Sinica B

www.elsevier.com/locate/apsb
www.sciencedirect.com



REVIEW

Role of vitamin D receptor in the regulation of *CYP3A* gene expression



Xuan Qin, Xin Wang*

Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China

Received 25 November 2018; received in revised form 28 February 2019; accepted 15 March 2019

KEY WORDS

Vitamin D₃;
VDR;
CYP3A;
Transactivation;
Pharmacokinetic;
Drug metabolism

Abstract Vitamin D₃ (VD₃) is a multifunctional nutrient which can be either synthesized or absorbed from the diet. It plays a pivotal role in systemic calcium and phosphate homeostasis, as well as in various physiological and pathological processes. VD₃ is converted to the active form, 1,25-dihydroxyvitamin D₃ (1,25-D₃), by cytochrome P450 2R1 (CYP2R1)/CYP27A1 and CYP27B1 sequentially, and deactivated by multiple enzymes including CYP3A4. On the other hand, 1,25-D₃ is capable of activating the transcription of *CYP3A* genes in humans, mice and rats. The vitamin D receptor (VDR)-mediated transactivation of human *CYP3A4* and *CYP3A5* resembles that known for pregnane X receptor (PXR). Activated VDR forms a heterodimer with retinoid X receptor α (RXR α), recruits co-activators, translocates to the cell nucleus, binds to the specific vitamin D responsive elements (VDRE), and activates the gene transcription. In mice, intestinal *Cyp3a11* mRNA levels, but not those of hepatic CYP3As, were induced by *in vivo* administration of VDR and PXR agonists. In rats, intestinal *Cyp3a1* and *Cyp3a2* mRNAs were induced by 1,25-D₃ or lithocholic acid (LCA), whereas hepatic *Cyp3a2*, but not *Cyp3a1* and *Cyp3a9*, was modulated to 1,25-D₃ treatment. In general, the VDR-mediated regulation of CYP3A presents species and organ specificity.

© 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

*Corresponding author. Tel.: +86 21 2420 6564; fax: +86 21 5434 4922.

E-mail addresses: usxinwang@gmail.com, xwang@bio.ecnu.edu.cn (Xin Wang).

Peer review under responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.

<https://doi.org/10.1016/j.apsb.2019.03.005>

2211-3835© 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Vitamin D₃ (VD₃), is an important nutrient which can be either synthesized or absorbed from the diet. Traditional roles for VD₃ are the maintenance of calcium and phosphate homeostasis. Mechanisms for regulating intestinal calcium absorption and renal reabsorption are well understood¹. In positive dietary calcium balance, VD₃ mediates systemic calcium absorption through intestinal epithelial calcium channels expressed on the brush border membrane. Well-known examples include transient potential vanilloid type 6 (TRPV6) and calbindin-D_{9k} channels. Serum calcium is largely responsible for the mineralization of bone matrix. In negative calcium balance, the osteoclast calcium reabsorption is repressed and bone calcium is released into the blood stream to rectify hypocalcemia. The VD₃-facilitated transcellular transport processes of phosphate are similar to those of calcium, and are controlled by sodium-dependent phosphate co-transporters such as sodium-dependent phosphate co-transporter 2b (NPT2b)^{2,3}. Global vitamin D receptor (*Vdr*) knockout (KO) mice developed abnormalities including hypocalcemia, secondary hyperparathyroidism and hypophosphatemia after weaning due to the impaired 1 α ,25-dihydroxyvitamin D₃ (1,25-D₃)-dependent intestinal calcium transport. These symptoms were further resolved after the local knock-in of *Vdr* in intestinal epithelial cells⁴. The kidney is another traditional target organ for VD₃. Renal calcium reabsorption in the distal tubules and phosphate reabsorption in the proximal tubules are also regulated by 1,25-D₃¹. Apart from the intestine and kidney, the direct functions of VD₃ on bone are controversial. Although one perspective views of this signaling as “redundant”; another suggests that VD₃ stimulates bone formation and mineralization in human osteoblasts *via* several cellular signaling pathways^{4,5}.

In recent decades, pleiotropic functions of VD₃ (including its active metabolites, collectively mentioned as VD₃) in physiological and pathological conditions have been gradually revealed. This has occurred in part due to increased understanding of the nuclear receptor VDR. Expression profiling shows that VDR is present not only in classical VD₃-target organs (intestine, kidney, bone, parathyroid glands, etc.) but also in many other cells with diverse derivations⁴. Newly-discovered VD₃ functions indicate its participation in the progression of diverse diseases including metabolic syndromes^{6,7}, infections⁸, cardiovascular diseases⁹, cancers^{10,11}, and even central nervous system disorders^{12,13}. VD₃ exhibits diverse effects in animals and humans because it participates in a plethora of biological processes such as proliferation, inflammation, and metabolism^{1,14}. Moreover, the fundamental VDR-mediated pathway has become recognized in the regulation network of drug metabolism enzymes.

Xenobiotic biotransformation mechanisms are critical for inactivation and disposal of both externally-ingested drugs as well as endogenous substances. Orally-administered drugs commonly undergo the processes of absorption, distribution, metabolism and excretion *in vivo*¹⁵. Cytochrome P450 (CYP) enzymes, consisting of several subfamilies and further divided into isoforms, are responsible for the metabolism of most drugs. Human CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 participate in about 90% of known phase I drug metabolic reactions¹⁶. Among these CYPs, CYP3A4 is the most abundant isoform in human liver and intestine, and plays significant roles in the biotransformation of the greatest number of endobiotics and xenobiotics¹⁷. CYP3A4 expression and activity are strictly regulated by transcription factors and upstream nuclear receptors, among which the most

extensively studies are pregnane X receptor (PXR) and constitutive androstane receptor (CAR). PXR and CAR ligands are largely exogenous compounds, indicating complex interaction between xenobiotics and the body¹⁸. On the contrary, VDR, which regulated by levels of endogenous ligands including VD₃, can control homeostatic CYP3A4 activity. Because VD₃ can serve as both an endogenous signaling molecule and a nutrient, its bioavailability is subject to complex regulation, with further implication for the transcriptional activities of *CYP3A* genes¹⁹.

In this review, we first introduce the *in vivo* metabolism profile of VD₃, and the mediation of *Cyp3a* gene transcription by PXR and CAR in humans, mice and rats. We then focus on the species-specific VDR-dependent regulation of human (CYP3A4, CYP3A5 and CYP3A7), mouse (mainly CYP3A11 and CYP3A13), and rat (mainly CYP3A1, CYP3A2 and CYP3A9) CYP3A isoforms (Table 1). In particular, these relationships and mechanisms may help us understand the intra- and inter-individual deviation of human CYP3A4 expression levels, and partly explain the important phenomena of varied oral drug bioavailability.

2. Biotransformation of VD₃

VD₃ can be supplied by either diet or endogenous biosynthesis. 7-Dehydrocholesterol, an intermediate in cholesterol biotransformation, is converted to VD₃ in the skin by exposure to ultraviolet B (UVB) in the sunlight. VD₃ is then converted to 25-hydroxyvitamin D₃ in the liver, by several CYP enzymes including CYP2R1, CYP27A1, CYP2D25, CYP2J2, and CYP3A4. As a major circulating form of VD₃, 25-hydroxyvitamin D₃ is transported to the kidney by vitamin D binding protein. In the proximal renal tubule, 25-hydroxyvitamin D₃ is further catalyzed to 1,25-D₃, the most active form of VD₃, by CYP27B1. 1,25-D₃ can be deactivated through the metabolism by CYP24A1 to 1,24,25-trihydroxyvitamin D₃ or 1,23,25-trihydroxyvitamin D₃ in the kidney, and is finally oxidized to calcitric acid by the same enzyme. Furthermore, CYP24A1 is also responsible for the hydroxylation of 25-hydroxyvitamin D₃^{1,38}. Recently, the functions of other CYPs (*e.g.*, CYP11A1) in VD₃ biotransformation have been identified, further enhancing our knowledge of VD₃ metabolism^{14,39}. Besides phase I metabolism, VD₃ and its metabolites also undergo phase II conjugation. For example, 1,25-D₃ is able to be glucuronide-conjugated at the 25-hydroxyl position, mainly by UDP-glucuronyl transferase (UGT) 1A4 and to a less extent by UGT2B4 and UGT2B7. The conjugates are excreted with the bile into intestine, and further re-absorbed into the enterocytes⁴⁰.

Human CYP3A4 is highly expressed in the liver and intestine, where VD₃ exercises its main functions by regulating calcium absorption. Although CYP3A4 is not previously identified as the major enzyme responsible for the activation or deactivation of VD₃, its catabolic activity towards VD₃ and its hydroxylated metabolites has been increasingly revealed^{41,42}. The CYP3A4 metabolites have been previously designated as “inactive” and CYP3A4-mediated metabolic processes are regarded as “deactivation”. However, some physiological effects, especially the anti-tumor activities of CYP3A4 metabolites, support a broader view for the protective and regulatory effects of VD₃ *in vivo*⁴². In humans, CYP3A4 catalyzes the 24- or 25-hydroxylation of 1-hydroxyvitamin D₃, the 23- or 24-hydroxylation of 1,25-D₃, and the 4 β -hydroxylation of 25-hydroxyvitamin D₃^{41,43}. These reactions mainly occur in the liver and/or the intestine, and the concentration of the product, 4 β ,25-dihydroxyvitamin D₃, is equal to that of 1,25-D₃ in plasma¹⁹. Previous studies reported that in

Table 1 A summary of differentiated responses to VDR ligands by different organs and species.

Species	Organ	CYP3A isoform	1,25-D3 treatment	Ref.	LCA treatment	Ref.
Human	Liver	3A4	↑ ^a — ^b	20 21	↑ ^b \	22,23
		3A5	—	21	\	
		3A7	—	21	\	
	Intestine	3A4	↑	24,25	↑	22,26
		3A5	—	20,27	\	
		3A7	—	20,27	\	
	Prostate	3A4	↑	28	\	
		3A5	↑	28	\	
		3A7	—	28,29	\	
		3A43	↑	29	\	
Mouse	Liver	3A11	↑	30	↑	23
	Intestine	3A11	↑	30,31	↑	23,30
Rat	Liver	3A1	—	32,33	—	34
		3A2	↑	32,33	—	34
		3A9	—	34,35	↑	34,35
	Intestine	3A1	↑	33	↑	33
		3A2	↑	33	↑	33
		3A9	—/↑ ^d	35–37	↑ ^{c,d}	34

↑ Up-regulated after treatment; — unaffected after treatment; \ not studied.

^aPrimary hepatocytes.

^bHepatocarcinoma cell lines.

^cPXR-mediated.

^dUncertain.

human hepatic and intestinal microsomes, the 23- or 24-hydroxylation rates of 1,25-D3 were highly correlated with that of midazolam 1'-hydroxylation, and were significantly inhibited by ketoconazole⁴⁴. Therefore, long-term use of some antiepileptic drugs might cause CYP3A4 induction as well as increased turnover of systemic VD₃, and the phenomenon of negative bone mineral balance⁴⁴. Similar effects were also observed after PXR agonist treatment on LS180 cells derived from human colon adenocarcinoma⁴⁵. In contrast, CYP3A4 inhibitors including chemicals and herb monomers inhibited the biotransformation of 1,25-D3 to 1,23S,25-trihydroxyvitamin D₃ and 1,24R,25-trihydroxyvitamin D₃^{43,46}.

3. Regulatory roles of PXR and CAR on CYP3A in different species

Human CYP3A4 induction by xenobiotics and hormones has been studied for many years. It is commonly believed that its regulation is involved with PXR (NR1I2), CAR (NR1I3), VDR (NR1I1), glucocorticoid receptor- α (GR α , NR3C1), hepatocyte nuclear factor-4 α (HNF4 α , NR2A1), HNF3 γ , CCAAT/enhancer-binding protein α (C/EBP α) and C/EBP β in the liver^{47,48}. Among these nuclear receptors involved, the interplay between PXR and/or CAR and CYP3A genes has been most extensively explored. The complexity of PXR- or CAR-mediated CYP3A induction lies in the broad panel of their ligands, which consist of endogenous steroids and exogenous chemicals. It is noteworthy that some ligands exhibit species selectivity, thus their affinities for the receptors vary across species¹⁸. For instance, the human PXR (hPXR) agonist, rifampin (RIF), was unable to bind rat or mouse PXR^{18,49}. This was verified by the up-regulation of CYP3A11 expression in PXR/CAR double humanized mice after RIF treatment, while the hepatic CYP3A11 activity remained unchanged in normal mice⁵⁰. On the contrary, pregnenolone 16 α -carbonitrile

(PCN) was a selective mouse PXR (mPXR) or rat PXR (rPXR) agonist⁵¹. Similar phenomena were also observed for CAR ligands. For example, 6-(4-chlorophenyl)imidazo[2,1-*b*][1,3]thiazole-5-carbaldehyde *O*-(3,4-dichlorobenzyl) oxime (CITCO) selectively bound human CAR (hCAR)⁵², while 1,4-bis[2-(3,5-dichloropyridyl-oxy-)]benzene (TCPOBOP) only activated mouse CAR (mCAR) but not hCAR⁵³.

In untreated rodent or human hepatocytes, PXR or CAR is stabilized by cytoplasmic co-chaperone partners like heat shock protein 90 (HSP90, Fig. 1). Upon ligand binding, the nuclear receptors are freed and translocated into the nucleus, identified as a pivotal step in PXR- or CAR-mediated transactivation¹⁵. The regulation of PXR on CYP3A transcription can thus follow these steps: the binding of ligand to the receptor, the formation of a heterodimer with the retinoid X receptor α (RXR α), the recruitment of co-activators (for example, the steroid receptor co-activators 1, SRC-1), the binding to PXR-response elements (PXREs), and the transcriptional regulation of target genes. The DNA response elements include direct repeats (DR)-3, DR-4, DR-5 and everted repeats (ER)-6 and ER-8. PXR agonists robustly activated the transcription of *Cyp3a* genes in different species, while compounds might suppress the constitutive and inductive CYP3A4 expression by interfering the processes in PXR-mediated transcription^{54,55}. The transactivation process by CAR is similar, except for the binding of CAR-RXR α complex to the phenobarbital responsive enhancer modules (PBREM) of the target genes^{18,49}. The binding to PBREM was specially discovered in the regulation of human *CYP2B6* or mouse *Cyp2b10* genes, but it was reported that human CYP2B6 and CY3A4 shared crossed substrate specificity and regulation networks⁵⁶. CAR was also found to transactivate the steroid/RIF-responsive ER6 motif of the human *CYP3A4* gene⁵⁷. These facts indicate the versatility of PXR and CAR in the regulation of target genes to some extent.




Figure 1 Vitamin D receptor (VDR)-mediated transactivation of *CYP3A4* gene. When it is not bound with ligands, VDR is retained with chaperone proteins (for instance, the heat shock protein 90, HSP90) in the cytoplasm. Activated by ligands like 1,25-dihydroxyvitamin D₃ (1,25-D₃) or lithocholic acid (LCA), VDR forms a heterodimer with retinoid X receptor α (RXR α), recruits coactivators (including, but not restricted to the steroid receptor coactivators 1, SRC-1), translocates into the nucleus, binds to the vitamin D response element (VDRE) of *CYP3A4* promoter, and up-regulates *CYP3A4* transcription. Human pregnane X receptor (PXR) and constitutive androstane receptor (CAR) transactivates *CYP3A4* in a similar manner, except for different ligands (rifampin, RIF, for PXR and 6-(4-chlorophenyl)imidazo[2,1-*b*][1,3]thiazole-5-carbaldehyde *O*-(3,4-dichlorobenzyl)oxime, CITCO, for CAR) and response elements in the gene promoter (PXR-response element, PXRE, for PXR and phenobarbital responsive enhancer modules, PBREM for CAR).

The inductive effects of PXR or CAR ligands depend on the organ-specific expression of the nuclear receptors. PXR is primarily expressed in rodent and human livers, as well as human testis and mouse intestine. CAR is abundant in rodent and human liver and kidney, and is also detected in human brain or mouse intestine¹⁸. The regulatory effects of PXR and CAR agonists on human *CYP3A4* are overlapping but biased. Although both RIF and CITCO are able to significantly activate the transcription of *CYP3A4* and *CYP2B6* in human primary hepatocytes, comparatively, RIF is more effective in *CYP3A4* induction, and CITCO is a more potent inducer of the latter gene⁵². Treatment with RIF significantly increased *CYP3A4* mRNA levels and *CYP3A4* catalytic activities in Caco-2 and LS-180 cells, which lead to the elevated catabolism of many active endogenous substances including 1,25-D₃⁴⁵.

For mouse, PCN was capable of inducing *Cyp3a11* transcription in both liver and intestine, while TCPOBOP only induced

hepatic *Cyp3a11* mRNA levels. These effects were not observed in *Pxr*- or *Car*-null mice⁵⁸. In rat hepatic slices, *Cyp3a1* was induced by the PXR ligand, PCN, and the PXR/GR ligand, dexamethasone; *Cyp3a2* transcription was suppressed by the GR ligand, budesonide; *Cyp3a9* was induced by all of the three ligands³⁴. On the contrary, the involvement of CAR in the induction of rat CYPs has rarely been studied. Besides the phase I metabolic enzymes, PXR and/or CAR also participates in the regulation of mouse hepatic phase II metabolic enzymes (UDP-glucuronosyltransferases, *Ugt1a1*; sulfotransferases, *Sultn*; glutathione *S*-transferases, *Gsta1*, *Gstm1*, *Gstm2* and *Gstm1*) and transporters (multiple drug resistance gene, *Mdr1a*, *Mdr1b*; multidrug resistance-associated protein, *Mrp2* and *Mrp3*) in distinct but overlapping manners⁵⁸.

4. Regulatory roles of VDR on CYP3A in different species

4.1. Human

4.1.1. Mechanism of VDR-mediated human *CYP3A* transactivation

The regulatory effects of VDR on human *CYP3A*s are believed to share common mechanisms with those of PXR (Fig. 1). The high similarity in the DNA-binding domains (64%) between PXR and VDR indicates overlapping transactivation motifs. On the other hand, the relative low similarity of their ligand-binding domains (37%) accounts for the discrepancies in their activating modes⁵⁹. It was assumed that the extremely large binding pockets of PXR and VDR observed in X-ray crystallographic assays enabled them accessible to ligands of diverse structures²⁶. Along with the flexibility in binding diverse DNA motifs, the nuclear receptors might regulate the transcription of an enormous panel of genes⁶⁰. VDR is located in the cytosol of VD₃-sensitive cells. When VDR is bound by 1,25-D₃, the complex forms a heterodimer with RXR, translocates to the cell nucleus, binds to the specific DNA-sequences referred to as vitamin D responsive elements (VDRE), and activates or represses the transcription of related genes^{1,38}. VDR and PXR also share similar responsive elements in the *Cyp3a4* gene promoter such as ER6, DR3 (dNR1), DR4 (eNR3A4)^{28,61}. From the experiment results of human intestine- or colon-derived cell lines (for instance, Caco-2 and LS180), two transactivation motifs were identified: the distal DR3 motif and the proximal DR6 motif, which were essential for the induction of this gene by 1,25-D₃⁶². The two relevant VDREs consist of distinctly diverse DNA motifs and are far separated in the promoting sequence of the gene. The distal DR3 motif is similar to the classic elements in those 1,25-D₃ targeting genes, and is localized almost 8000 bp upstream of the starting site of *CYP3A4* transcription²⁶.

The sequence conservation of both the distal DR3 motifs and the proximal DR6 motifs in the *CYP3A4* promoter is pivotal to the transactivation functions of VDR-RXR on *CYP3A*s⁶². *CYP3A4* and *CYP3A5* are highly related in genes sequences (89%). *CYP3A5*, however, lacks a distal xenobiotic-responsive enhancer module (XREM) region (−7836 to −7208 bp) containing ER6 and DR3 motifs. It was able to bind HNF4 α compared with *CYP3A4* and *CYP3A7*^{63,64}. This dissimilarity may be the reason for the differential regulatory mechanisms between *CYP3A4* and *CYP3A5*. For the induction of *CYP3A5*, some studies mentioned the involvement of GR, PXR and CAR in the liver and intestine⁶⁵. Others pointed out that neither its basal expression in extrahepatic

tissues was dependent on PXR, nor its transcription was responsive to PXR ligands⁶⁶. Neither the hepatic nor intestinal *CYP3A5* genes were sensitive to VDR ligands (discussed in next sections). Levels of *CYP3A7*, a human fetal form of hepatic *CYP3A* that decline along with the increased expression of *CYP3A4*⁶⁵, were not induced by 1,25-D₃. Comparisons of the proximal ER6 motif of *CYP3A7* with that of *CYP3A4*, found two nucleotide mutations (-169G→-168T, -161A→-160T) and a 10-nucleotide deletion corresponding to the region between -295 and -286 bp of *CYP3A4* proximal promoter⁶². These two mutations, but not the deletion, may account for the fact that PXR-RXR α and VDR-RXR α are no longer able to recognize and bind the promoter sequence of *CYP3A7* and activate the transcription of this isoform^{21,62}. In fact, a *CYP3A7* gene polymorphism (*CYP3A7*IC*) has been identified with high *CYP3A7* expression in adult liver and intestine. *CYP3A7* and *CYP3A7*IC* allele carriers had differential sequences in the ER6 motif of the gene promoters⁶⁷. The nucleotide sequence of the latter (identical to that of *CYP3A4*) made it sensitive to PXR-mediated promoter activation, and probably also susceptible to VDR-mediated transactivation⁶². *CYP3A43* was the fourth member of human *CYP3A* genes, with 75.8% amino acid sequence identity to *CYP3A4*. Highest expression of *CYP3A43* mRNA is in the prostate, with detectable levels in the brain, placenta, liver, and testis^{68,69}. Moreover, *CYP3A43* was detected in all Caucasian liver samples, but its levels varied up to 1000-fold. In human primary hepatocytes, *CYP3A43* was also susceptible to RIF induction^{68,70}. However, the responses of *CYP3A43* to some other known *CYP3A4* inducers were differentiated⁷¹. Little is known yet about the metabolic capacity of *CYP3A43* on VD₃, but the substrate selectivity between *CYP3A4* and *CYP3A43* is substantial.

The relationship between PXR and VDR on *CYP3A4* induction is controversial. For example, one study showed that VDR and PXR synergistically cooperate in the transactivation of *CYP3A4* reporter in an intestinal cell line, LS174T⁶¹, whereas another study contrastingly reported competition between VDR and PXR on the regulation of *CYP3A4* in HepG2 cells. The effects of PXR on *CYP3A4* seemed to predominate over those of VDR when the two plasmids were co-transfected and the two ligands (RIF and 1,25-D₃) were simultaneously given⁷². Considering the different resources of the cell lines used in the two studies, the controversy might be explained. As it will be discussed in the next section, PXR was predominantly expressed in the liver, while VDR levels were higher in the intestine. However, high basal expression level of VDR was detected in LS174T⁶¹, while the authors suggested low endogenous level of PXR and VDR in HepG2 cells⁷². Therefore, the interaction between the two nuclear receptors on the regulation of *CYP3As* could be tissue-specific and ligand-dependent, but also be associated with the basal expression profiles of the nuclear receptors. The relationship between PXR and VDR, although poorly understood, may contribute to the complexity of the regulatory network of xenobiotic metabolic enzymes. There is notable overlap in the regulatory functions of PXR and VDR. By sharing the transactivating motifs with PXR, the VDR-RXR α heterodimer was also able to activate the expression of human *CYP2B6* and *CYP2C9*, although the effect on the latter enzyme was more modest^{47,72}. For comparison, protein levels of *CYP1A1* and *CYP2D6* were not influenced by 1,25-D₃ treatment²⁷. Interestingly VDR also participates in the regulation of phase II metabolic enzymes, such as *UGT2B15/2B17*^{29,73} and *SULT2A1*⁷⁴. Furthermore, VD₃ has been shown to up-regulate efflux transporters including *MDR1*, *MRP2*,

MRP3, as well as *MRP4*^{24,74,75}, and uptake transporters such as organic anion transporting polypeptide 1A2 (*OATP1A2*)⁷⁶, which share same VDREs with *CYP3A4*.

Some studies also disclosed that many protein kinases are involved in the interaction between 1,25-D₃ and *CYP3A4*. Thus, 1,25-D₃ induced the expression of *CYP3A4* by both ligand-dependent and ligand-independent mechanisms. Using specific protein kinase inhibitors, the participation of protein kinase C (PKC), tyrosine kinase, mitogen-activated protein kinases (MAPKs) and c-Jun N-terminal kinase (JNK) was identified, whereas protein kinase A (PKA), extracellular signal-regulated kinase (ERK) and p38 were not relevant^{77,78}. The authors suggested that 1,25-D₃ activated PKC and JNK through a non-genomic signal pathway, and the activated protein kinases recruited transcriptional factors like AP-1 and Sp-1, assisting the transactivation effects of VDR on *CYP3A4*⁷⁸.

4.1.2. Results from cell lines

Most studies focus on the effects of VDR on the major human *CYP3A* isoform, *CYP3A4*, and are most commonly conducted with intestine and/or liver tissue, in which the expression of *CYP3A4* is abundant. In contrast to PXR, VDR recognizes a narrow ligand spectrum, including bile acids and VD₃ (including its metabolites and derivatives)²¹. The affinity of the ligands for VDR follows the rank order: 1,25-D₃>25-hydroxyvitamin D₃>VD₃, and higher activating capacities of VDR result in stronger *CYP3A4* induction⁴⁷. That is, 25-hydroxyvitamin D₃ was able to increase *CYP3A4* catalytic activity, although to a less extent compared with 1,25-D₃, and the unhydroxylated VD₃ had no effect of inducing *CYP3A4* protein expression or activity²⁷.

Although liver and intestine are both significant in the first-pass metabolism of orally-administered substances, the expression and regulation of nuclear receptors and catabolic enzymes are distinct between these tissues. PXR is abundant in hepatocytes, but is not predominant in the regulation of intestinal *CYP3As*¹⁸. On the contrary, VDR is highly expressed in intestine- or colon-derived cell lines, but not in liver-derived cell lines or parenchymal cells¹⁹. The expression levels of VDR correlates with those of intestinal *CYP3A4* which gradually decreases from the proximal small intestine to the colon. The effects of 1,25-D₃ on intestinal *CYP3A4* were uncontroversial, fast and dose-dependent according to *in vitro* studies. The transcription of *CYP3A4* in intestinal cell lines (LS180 and Caco-2) was induced by 1,25-D₃ in nanomolar levels, which necessitated the expression of VDR, but not PXR²⁴. *CYP3A4* mRNA amplification occurred only 6 h after 1,25-D₃ treatment, and prolonged treatment duration led to further increases²⁵. *CYP3A4* protein levels and catalytic activity were also quickly up-regulated after 1,25-D₃, 25-hydroxyvitamin D₃ or 1 α -hydroxyvitamin D₃ treatment in Caco-2 cells, but *CYP3A5* or *CYP3A7* protein levels were not induced by 1,25-D₃ in either Caco-2 nor HPAC (pancreatic adenocarcinoma) cell lines^{20,27}.

In contrast, conclusions on whether *CYP3A4* could be induced by 1,25-D₃ in hepatic cell lines were inconsistent. For instance, one study reported both basal and calcitriol-induced *CYP3A4* expression in the hepatocarcinoma-derived HepG2 cells⁷⁹. On the contrary, another study concluded that HepG2 cells were not a good tool to study *CYP3A4* induction, because in this cell line *CYP3A7* was expressed instead of *CYP3A4*, and *CYP3A4* was not induced by RIF despite the presence of PXR. Moreover, *CYP3A4* mRNA levels were also unaffected by 1,25-D₃ treatment²¹. The controversial results from these two articles may be

due to the different 1,25-D₃ concentrations (100 and 250 nmol/L vs. 1 and 100 nmol/L) and/or treatment durations (up to 144 h vs. 48 h). Interestingly, different from the nonresponsiveness in HepG2, *CYP3A4* transcription in primary human hepatocytes was susceptible to 1,25-D₃ treatment²⁰. Khan et al.³⁴ suggested that VDR might be expressed more abundantly in human hepatocytes compared with rat hepatocytes or human hepatocarcinoma cell lines. Therefore, the differentiated results by known PXR or VDR ligands from HepG2 and human primary hepatocytes may be attributed to the loss of nuclear receptors and the changes of enzyme profiles in the carcinoma-derived cell line.

Although *CYP3A4* is mainly expressed in the intestine and liver, its existence and functions in other organs and tissues are gradually being revealed. Extrahepatic *CYP3A4* is usually responsible for the *in situ* metabolism of hormones and signal molecules. For instance, *CYP3A4* participates in the irreversible oxidation of testosterone and terminates its androgenic effects in prostate⁷³. Androgens including androstenedione, dehydroepiandrosterone, testosterone and dihydrotestosterone serve as substrates of *CYP3A4*. 1,25-D₃ treatment significantly increased the gene transcription of *CYP3A4*, *CYP3A5*, *CYP24A1* and *VDR* but not *AR* (androgen receptor) in LNCap or LAPC-4 cells. *CYP3A5* was more responsive to 1,25-D₃ than *CYP3A4* in LAPC-4 cells. 1,25-D₃ also increased the enzymatic level of *CYP3A4* and its catalytic activity (measured by the turnover velocities of testosterone and dehydroepiandrosterone). Enhanced *CYP3A4/3A5* activities accelerated the catabolism of testosterone and inhibited cell growth, while in the presence of the *CYP3A4* inhibitor, ritonavir, the anti-proliferative effects of 1,25-D₃ were partly impaired²⁸. In contrast, the expression of *CYP3A7* was independent of VDR regulation^{28,29}. The synthetic VDR agonist, EB1089, had similar effects on *CYP3A4*, *CYP3A5* and *CYP3A7* genes as 1,25-D₃. Surprisingly, *CYP3A43* mRNA was significantly induced by EB1089. The functions of VDR on *CYP3A4* in LNCap and LAPC-4 cells seemed exclusive, as the expression levels of PXR and FXR were negligible in these two prostatic cancer cell lines²⁹. Therefore, VDR may partly exert its anti-proliferative effects by inducing *in situ* *CYP3A4* level and modulating androgen metabolism.

4.1.3. Results from organ slices

CYP3A4, *CYP3A5* and *CYP3A7* belong to three categories of metabolic enzymes considering their differential expression profiles in fetuses and infants. *CYP3A7* is highly expressed in the first trimester in gestation and gradually decreases afterwards. *CYP3A5* is steadily expressed until 1–2 years after birth. *CYP3A4* protein level is extremely low in the first trimester, but increases quickly in the second and third trimester of pregnancy⁸⁰. Regarding basal *CYP3A* expression, significant correlations between *VDR* and *CYP3A4/3A7* mRNA levels in fetal liver tissue, and between *VDR* and *CYP3A4* mRNA levels in fetal intestine tissue, were established⁸¹. Another study indicated that 1,25-D₃ was an essential auto/paracrine hormonal factor for the complex regulation of several VD₃-responsive genes and fetal gut development. In both proximal and distal intestine and colon in specimens from fetuses 15–20 weeks after gestation, *VDR* and *CYP3A4* mRNA were detected. *CYP3A4* was greatly induced by 1,25-D₃, while the effects also showed significant inter-individual variability. That is, in one of the four specimens, *CYP3A4* mRNA level was not influenced by 1,25-D₃ treatment. In addition, there were positive relative relationships between the induction profiles of *CYP3A4* and the VD₃ 24-hydroxylase *CYP24A1*⁸².

In adults, the enterohepatic circulation of VD₃ and its metabolites may be a factor for the preferential expression of VD₃-target genes in the proximal intestine compared with the distal intestine. Radiolabeled 1,25-D₃ and 25-hydroxyvitamin D₃ were discovered in the bile and afterwards re-absorbed into the intestinal epithelial cells. High local concentrations of active VD metabolites efficiently motivated the expression of VD₃-responsive genes such as *CYP3A4* and *TRVP6*¹⁹. There was no correlation between the basal mRNA levels of *VDR* and *CYP3A4/3A7* in adult liver tissues⁸¹, but *CYP3A4* was strongly induced in human ileum slices *ex vivo* by VDR, PXR and GR ligands, which was in accordance with the results observed in human intestinal cell monolayers. Similar results were also obtained in human liver slices, but were restricted to the samples in which VDR was expressed³⁵.

4.1.4. Results from patients

No apparent correlations have been reported between the intestinal and hepatic *CYP3A4* expressions or catalytic activities in individuals. Much higher *CYP3A4* levels were found in enterocytes vs. hepatocytes, which play a significant role in the gut biotransformation of many substrates⁸³. Due to the differential localization of VDR in liver and intestine, the regulation of *CYP3A4* expression by VD₃ and VDR may be one of the organ-specific factors. Some studies pointed out that seasonal variation in sunlight exposure and plasma VD₃ levels could theoretically account for fluctuating *CYP3A4* levels over the year, and would hence influence drug turnover³⁸. For instance, chronically administered *CYP3A4* substrates such as the immunosuppressants sirolimus and tacrolimus had significantly lower concentration/dose ratios (–17% and –5%, respectively) during the summer months, compared to those in the winter in Sweden. Comparatively, the *CYP3A5*-mediated metabolism of these drugs was less influenced by the seasonal variation of UVB exposure and intrinsic VD₃ levels⁸⁴. Abundant evidence verified that pathological conditions were capable of altering metabolic enzyme expression and activity, and hence the *in vivo* profiles of drugs and endogenous substances. In patients with end-stage renal disease, the decrease of 1,25-D₃ and the accumulation of uremic toxins contributed to the decreased hepatic clearance of *CYP3A4* substrates⁸⁵.

In a clinical trial of 87 patients with abnormal glucose homeostasis or diabetes, no significant changes were seen in hepatic *CYP3A4* activities (measured as delta serum 4β-hydroxycholesterol/cholesterol ratio), although patients receiving 30,000 IU of oral VD₃ once a week for 8 weeks had increased mean serum concentrations of 25-hydroxyvitamin D₃. Nonetheless, the authors thought it could not exclude the possible alterations in the intestinal metabolism of oral drugs after high doses of VD₃ administration⁸⁶. Atorvastatin, a β-hydroxy-β-methylglutaryl-CoA (HMG-CoA) reductase inhibitor for the treatment of hyperlipidemia, is metabolized to two active metabolites by *CYP3A4* *in vivo*, which are then further deactivated by *CYP3A4*. In a clinical trial of 16 patients, the group taking atorvastatin along with VD₃ supplements showed lower bioavailabilities of atorvastatin and its metabolites. The lower total area under the curve (AUC) exhibited a trend (not significant) in correlation with higher active VD₃ plasma concentrations⁸⁷.

In conclusion, despite of insufficient clinical data, further studies are needed to establish relationships between *in vivo* *CYP3A4* activity and substrate bioavailability, as well as between *in vivo* *CYP3A4* activity and the elimination rates and systemic VD₃ levels influenced by seasonal, pathological or pharmacological factors.

4.1.5. Other VDR ligands

Apart from VD₃ and its mono-, di- and tri-hydroxylated metabolites and analogs, a carcinogenic secondary bile acid, lithocholic acid (LCA), also serves as an endogenous VDR ligand. Mutagenesis assays in the ligand binding domain of VDR indicated that S237 and S225/S278 were critical for 1,25-D₃ and LCA action, respectively²². LCA is transformed by intestinal bacteria from the primary bile acid, chenodeoxycholic acid (CDCA)⁸⁸. Interestingly, although primary bile acids only showed affinity for farnesoid X receptor (FXR) but not VDR, LCA (as well as its major metabolites) could activate both VDR and FXR⁸⁹. The LCA-VDR complex was also able to combine and activate the ER6 and DR3 motifs and induce the expression of CYP3A4 in HT-29 (a colon cancer cell line), although it was not as effective as 1,25-D₃ at the same concentration. The amplification effects correlated with the expression levels of VDR^{22,26}. Similar effects of LCA and 1,25-D₃ in activating VDR were also observed in HepG2, LST174, kidney COS-7 cell line and human HEK-293 cell line) and rat osteoblast-like osteosarcoma cell lines^{22,23}. The inductive effects of LCA were observed at lower concentrations and higher extents in LST174 cells compared with HepG2 cells. These effects were believed to work through the VDR-mediated pathway rather than the PXR-mediated pathway as they could be attenuated by the introduction of small interference RNA (siRNA) of VDR²³. Another reason of focusing on VDR rather than PXR was that the EC₅₀ values of either LCA or 3-keto-LCA (the metabolite of LCA) on PXR were 10 times higher than those on VDR. Therefore, the concentration of LCA used in the aforementioned experiments was insufficient to activate PXR³⁰. Transfection of exogenous CYP3A4 VDRE, RXR or SRC-1 into HT-29 cells seemed to enhance the effects of LCR-VDR complex more effectively compared with 1,25-D₃-VDR complex²².

In human ileum slices, LCA (10 μmol/L) significantly increased CYP3A4 expression in a time-dependent manner (accompanied with changes of MRP2 and MRP3 levels), although the effects were not consistent across all of the human liver slices³⁴. Conclusively, as a cytotoxic metabolite of CDCA produced by gut bacteria, LCA up-regulated the expression of CYP3A4 in both small and large intestines, promoting the detoxification of itself and reducing the risks of colon cancer²². The inductive effects of LCA on CYP3A4 gene was called a “feed-forward mechanism” as CYP3A4 efficiently 1β-hydroxylated LCA and prevented its accumulation. CYP3A4 is also capable of transforming LCA to 3-keto-LCA, a more potent ligand for PXR and VDR and regulator on CYP3A4 expression^{59,90}. Thus the constructive expression of CYP3A4 in enterocytes may be maintained by natural 1,25-D₃ that efficiently binds to VDR, and CYP3A4 transcription may be additionally elevated by high local concentrations of LCA to benefit the detoxification of this carcinogen²⁶.

There is a sustained medicinal chemistry effort to synthesize VDR ligands based on the crystal structure of this nuclear receptor, and to create analogs with a broad spectrum of physiological impact⁹¹. At the same time, agonist effects of some natural compounds on VDR are discovered, though these compounds are not similar to VD₃ in their chemical structures. Flavonoids are abundant in fruits, vegetables and beverages. Several studies suggest that some flavonoids also showed affinity towards VDR at relatively high concentrations. For instance, curcumin was identified as a low-affinity ligand for VDR *via* several assays. In particular, 10 μmol/L of curcumin resulted in equal effects on the transcription of the VDRE-reporter plasmid compared with

10 nmol/L of 1,25-D₃. Curcumin was also capable of competing with 1,25-D₃, binding to VDR directly and recruiting co-modulators like RXRα and SRC-1, and thus transactivating VDR-target genes, including CYP3A4⁹². Another study found that 3-day treatment of 50 μmol/L quercetin on Caco-2 cells slightly but significantly up-regulated VDR and VDR-target genes, including CYP24A1, CYP3A4, MDR1 and TRPV6, and the correlated higher expression of CYP3A4 and P-gp proteins were observed. Introduction of VDR siRNA suggested that the effects of quercetin on CYP3A4 required the normal functions of VDR in Caco-2 cells. Other quercetin-like flavonoids (kaempferol and berberine) of equal concentration and treatment duration resulted in similar effects on these genes⁹³. The inductive effects of complementary and alternative medicines (CAM) on CYP3A4 through PXR- or CAR-mediated pathway has been elucidated⁹⁴. It hence seems that VDR also plays an essential role in the interplay between flavonoids and CYP3A4. Although these compounds present relative weaker VDR affinity compared with 1,25-D₃, dietary intake can easily form a local environment with high flavonoid concentrations (micromolar levels) in the intestine. This raises concerns on diet-drug interactions, and whether long-term flavonoids intake will enhance VD₃ catabolism from induced CYP3A4 expression.

4.1.6. Gene polymorphism

The phenomenon of VDR gene polymorphism is frequently observed in clinic¹⁴. One set of VDR single nucleotide polymorphism (SNP) (FokI and EcoRV) is localized near its 5'-end, another (TaqI, BsmI and polyA) is near the 3' untranslated region. The FokI polymorphism, for example, results in a shorter VDR protein sequence⁹⁵. The inductive effects of 25-hydroxyvitamin D₃ on CYP3A4 may be largely confined to rs4516035 (GATA-1012A > G) AG/AA carriers, but the basal CYP3A4 activity in rs4516035 GG carriers is high in spite of low serum 25-hydroxyvitamin D₃ levels, and does not increase further with elevated 25-hydroxyvitamin D₃ concentrations⁹⁶. Thirumaran et al.⁹⁷ reported no association between VDR BsmI polymorphism (rs1544410, intron 8 BsmI-G>A) and hepatic CYP3A4 protein expression or intravenous midazolam clearance as VDR was not sufficiently expressed in human hepatocytes. However, VDR BsmI-G genotype was associated with higher intestinal CYP3A4 expression/activity quantified by oral midazolam clearance in Caucasian populations. The authors supposed that this VDR allele possessed a GATA binding site in VDR promoter that transactivated VDR, and thus induced the expression of CYP3A4 in intestine⁹⁷.

There is bidirectional regulation between VDR and CYP3A4. The major CYP3A4 allele rs2242480 (in intron 10, near the exon/intron boundary) is associated with higher serum 25-hydroxyvitamin D₃ concentrations among middle-aged and elderly Chinese in Singapore. Although the functional relevance of this SNP is unclear, a recent pharmacokinetic study suggests that individuals with the homozygous variant rs2242480 TT genotype have significantly lower CYP3A4 activity⁹⁸. This correlation might indicate the significance of CYP3A4 function in maintaining integrates 25-hydroxyvitamin D₃ levels, but the relationship and physiological outcomes needed more detailed research.

In short, we can partly conclude that factors like individual dietary habits and/or duration/intensity of sun exposure, might contribute to the intra- and inter-individual diversity of CYP3A4 expression. More importantly, when systemic or local VD₃ levels

fluctuate, the disposition of the drugs that serve as CYP3A4 substrates may be changed⁷². VDR-mediated *CYP3A4* induction could bring complex physiological and pharmacological consequences in at least two aspects. If drugs subject to CYP3A4 metabolism are taken along with VDR modulators or under pathological conditions (for instance, during cholestasis, LCA level was significantly increased), their bioavailability and disposition could be changed, and the potential for drug–drug interactions (DDI) should be carefully considered^{19,34}. On the other hand, as 1,25-D3 is not only an inducer but also a substrate of CYP3A4, enhanced 1,25-D3 catabolism in CYP3A4-abundant tissues (for example, the intestine) would influence the downstream regulation of apical membrane calcium transport protein expression, like TRPV6, and possibly impair the intestinal calcium absorption⁴⁵.

4.2. Mouse

The expression of five CYP3A proteins (CYP3A11, CYP3A13, CYP3A16, CYP3A25 and CYP3A44) was studied in mouse intestinal epithelial cells. Measured by mRNA levels, *Cyp3a13* was extensively transcribed in the intestine, while *Cyp3a41* was most abundant in the liver⁹⁹. In mouse liver, CYP3A13 was constitutively expressed, but was not an inducible isoform. In contrast, CYP3A11 was barely detected in liver homogenate until induced by, for instance, phenytoin. Similarly, in mouse brain, the expression of CYP3A13 was beyond the detection limit, while CYP3A11 was significantly induced by phenytoin treatment^{100,101}. Although VDR protein levels were much higher in mouse hepatocytes as compared with human or rat hepatocytes, VDR expression was still lower than in mouse duodenocytes¹⁰². Another study reported detection of mouse PXR in both mice liver and intestine, yet VDR was mainly present in the latter organ²³. VDR was also abundantly expressed in mouse kidney¹⁰³.

Mouse intestinal *Cyp3a11* mRNA level was responsive to the *in vivo* administration of VDR (1 α -hydroxyvitamin D₃ and LCA) and PXR ligands. The induction of *Cyp3a11* mRNA by LCA was independent of PXR validated by *Pxr* knockout mice³⁰. In *Pxr/Car* double null mouse hepatocytes, PXR (PCN) or CAR (TCPOBOP) agonists no longer triggered the transcription of *Cyp3a11*, but 1,25-D3 still induced *Cyp3a11* mRNA level³¹.

Increased *Cyp3a* mRNA levels were detected in the intestine but not in the liver of mice orally receiving 100 mg/kg/day LCA for 3 days. However, when mouse livers were transfected with human VDR adenovirus, the hepatic CYP3A expression was also induced by LCA. This result indicates that the inductive effect of LCA in mice is dependent upon VDR²³.

The bidirectional modulation between LCA and human intestinal CYP3A4 is well established. As known in the case of humans, LCA induces mouse *Cyp3a11*, and yet mouse intestinal CYP3As also play pivotal roles in detoxifying LCA. Cheng et al.¹⁰⁴ used a panel of mouse models to study LCA-caused hepatotoxicity. Toxicity was measured as increased alanine aminotransferase (ALT) and alkaline phosphatase (ALP) values in wildtype (WT) mice, mice with intestine-specific disruption of VDR mice (*Vdr* ^{Δ IEpC}), mice with transgenic-CYP3A4 (Tg-3A4), and mice with both intestine-specific disruption of VDR and transgenic-CYP3A4 (*Vdr* ^{Δ IEpC}/3A4). The severity of injury followed the order: *Vdr* ^{Δ IEpC}>WT, *Vdr* ^{Δ IEpC}/3A4>Tg-3A4. This order suggests that LCA hepatotoxicity can be aggravated in the absence of intestinal VDR, and may be alleviated by the genetic insertion of human *CYP3A4*. The authors also suggested that, in

Vdr ^{Δ IEpC} mice, the knockout of intestinal *Vdr* might result in the damage of intestine permeability, with an ensuing increase in the re-uptake of bile acids into the hepatocytes. Cholesterol and bile acids were thus more synthesized and accumulated in hepatocytes, which lead to more severe LCA toxicity. The excreted intestinal bile acids were metabolized by intestinal-specific expression of CYP3A4 in *Vdr* ^{Δ IEpC}/3A4 mice, and rescued the hepatocytes from excessive bile acid exposure¹⁰⁴.

4.3. Rat

Among the several rat CYP3A isoforms, CYP3A9, CYP3A18 and CYP3A62 have been detected in the intestine, whereas CYP3A1 and CYP3A2 are the main hepatic isoforms⁹⁹. Although the constitutive expression of CYP3A1/23 (mentioned as CYP3A1 in following discussion) (<https://www.ncbi.nlm.nih.gov/gene/25642>) was beyond detection limit in the intestine, it served as a main inducible isoform of CYP3A in rat intestine and liver¹⁰⁵. VDR is highly expressed in rat intestinal epithelial cells, while in liver, mRNA or protein of VDR is mainly detected in nonparenchymal cells (sinusoidal endothelial, Kupffer, stellate, and biliary epithelial cells) rather than hepatocytes^{33,102}. Except for the similarity in the preferential expression of VDR in intestinal mucosal epithelial cells vs. hepatocytes, rat *Cyp3a1* and human *CYP3A4* share common VD₃-responsive transcriptional enhancer elements¹⁰⁵. CYP3A1 is equally effectively induced by LCA and 1,25-D3, with the participation of *Cyp3a1* DR3 as a VDRE²². Compared with human *CYP3A4* DR3, the rat *Cyp3a1* PDR3 is localized much further upstream toward the gene²⁶. However, the mouse or rat *Cyp3a* genes lack a proximal DR6 element similar to that of human *CYP3A4*^{26,30}.

4.3.1. CYP3A1 and CYP3A2

The inductive effects of 1,25-D3 on rat CYP3As are dose-dependent, isoform-dependent and region-dependent. In the proximal rat intestine, *Cyp3a1* instead of *Cyp3a2* mRNA has been abundantly detected, but the induction of *Cyp3a2* was still observed after VDR ligand treatment. Incubation of 1,25-D3 with the precise slices of rat intestine significantly induced *Cyp3a1* mRNA levels, while the inducing effects differentiated among colon, ileum and jejunum. *Cyp3a2* mRNA was highly induced after incubation with 1,25-D3 in ileum slices, but not in jejunum and colon slices³². Intraperitoneal treatment of 1,25-D3 (100 ng) significantly and selectively elevated CYP3A1 mRNA and protein levels in male rat intestine. Apart from 1,25-D3, 8 h incubation with LCA (10 μ mol/L) or CDCA (50 μ mol/L) also induced *Cyp3a1* mRNA in rat ileum slices, yet *Cyp3a2* mRNA was only induced in 1,25-D3 or LCA groups. The inductive effects of 1,25-D3 and LCA on *Cyp3a1* and *Cyp3a2* were attenuated by CDCA in a dose-dependent manner (1–50 μ mol/L)³³.

In rat liver, VDR was only detected in cholangiocytes, where CYP3A2, but not CYP3A1 and CYP3A9, co-exist. Therefore, although hepatic *Vdr* mRNA level was significantly increased after 1,25-D3 treatment, only the mRNA level of *Cyp3a2* (in cholangiocytes), but not *Cyp3a1* (in hepatocytes), was simultaneously up-regulated^{32,33}. Hepatic *Cyp3a1* and *Cyp3a2* transcription were not affected by LCA incubation³⁴. Taking P-gp expression into consideration, experiments utilizing a dual substrate of P-gp and CYP3A showed the failure of VDR-mediated regulation on rat hepatic CYP3As. 1,25-D3 changed the *in vivo* distribution of quinidine by up-regulating the cerebral P-gp expression, but failed to alter its systemic clearance or turnover

rate in liver microsomal incubation¹⁰⁶. Hepatic CYP3A protein levels were not changed after 1,25-D3 treatment¹⁰⁶.

4.3.2. CYP3A9

For CYP3A9, the effects of 1,25-D3 treatment were not consistent. The transcription of *Cyp3a9* in rat colon, ileum or jejunum slices was strongly up-regulated by PCN, budesonide (a GR ligand) and dexamethasone (a PXR/GR ligand)³⁵, but less sensitive to PXR-mediated induction compared with *Cyp3a1*¹⁰⁵. On the contrary, some studies concluded that *Cyp3a9* was not induced by 1,25-D3, in either *ex vivo*³⁵ or *in vivo*^{32,105} experiments. The same laboratory, however, reported an approximate 2-fold increase of *Cyp3a9* mRNA levels in rat ileum, along with highly variable but significant increases in this mRNA from rat liver and kidney following repeated intraperitoneal dose of 2.56 nmol/kg or 6.4 nmol/kg 1,25-D3; *Cyp3a1* mRNA levels remained unchanged^{36,37}. The authors did not explain the discrepancy in results concerning *Cyp3a9*, but this might result from the different doses of 1,25-D3 used in the two experiments. In precise-cut slices from male rat jejunum, ileum and colon, 10 $\mu\text{mol/L}$ of LCA modestly induced *Cyp3a9* mRNA levels. However, the inductive trends of LCA from jejunum to colon did not resemble the relative abundance of VDR in the different parts. The authors presumptively attributed the induction of *Cyp3a9* to the interaction between 3-keto-LCA and PXR, instead of LCA or VDR, as 1,25-D3 failed to induce *Cyp3a9* expression³⁴. Thus 1,25-D3 was unable to induce rat hepatic *Cyp3a1*, *Cyp3a2* or *Cyp3a9* mRNAs, but hepatic *Cyp3a9* induction was only achieved when liver slices were incubated with a higher concentration of LCA (50 $\mu\text{mol/L}$) and a longer duration (24 h)^{34,35}.

Furthermore, some other studies discussed the effects of other synthesized VDR ligands on intestinal *Cyp3a9* transcription, and the results differed from those of 1,25-D3 and LCA. 1 α -Hydroxyvitamin D₂ (doxercalciferol), which was converted to the active form of 1,25-dihydroxyvitamin D₂ *in vivo*, was able to transactivate *Cyp3a9* in the rat liver and kidney, but not in the duodenum or ileum³⁷. 19Nor-1,25-dihydroxyvitamin D₂, a VD₂ analog for the treatment of secondary hyperparathyroidism, interestingly showed a significantly stronger dose-dependent inductive effect on *Cyp3a9* mRNA than 1,25-D3 in rat intestine. The authors identified a proximal VDRE at the position -119 to -133 from the starting site of transcription in the antisense strand of *Cyp3a9* promoter. Another distal VDRE, at the position -727 to -783, was more responsive to 19nor-1,25-dihydroxyvitamin D₂ than 1,25-D3. The cell- and gene-specific regulation of activated VDR-RXR complex on different VDREs might result from the abilities of recruiting differentiated co-regulators. Therefore, the binding profiles of VD₂ analogs to VDR might be differentiated from that of 1,25-D3, and the ligand-VDR complex might selectively bind to different VDREs in VDR-target genes. In addition, the abilities of inducing CYP3As of VD₂ analogs may not correlate with disturbing intestinal calcium absorption and causing hypercalcemia, which were the usual side effects of 1,25-D3^{1,107}.

4.3.3. Other rat CYP3A isoforms

Although CYP3A18 and CYP3A62 served as main rat intestinal CYP3A isoforms¹⁰⁸, little is known about their induction. Modulation of these by PXR, CAR or VDR ligands has not been investigated.

Rats are much bigger than mice and easier to handle, which provide convenience for the more detailed study on the VDR-mediated CYP3A induction. The precise slices from different

parts of the intestine (duodenum, jejunum, and ileum) and colon could be achieved, and the results discussed above indicated the differentiated expression of VDR and region-specific regulation on, for example, *Cyp3a1* and *Cyp3a2* mRNAs. The nonhomogeneous localization of CYP3A isoforms and VDR in different kinds of liver cells may also explain the isoform-specific induction after VDR ligand treatment. Nonetheless, many problems are still not solved as the results are sometimes inconsistent. For instance, there were controversial conclusions on the relative contributions of *Cyp3a1* and *Cyp3a9* genes to the total intestinal CYP3A protein. However, the enzymatic activity of rat intestinal homogenate (indicated as testosterone 6 β -hydroxylation activity) was not changed. The authors hypothesized that, as the constitutive expression of CYP3A1 was much lower than CYP3A9 in intestinal epithelial cells, the increased CYP3A1 levels were not sufficient to elevate the catalytic activities¹⁰⁵. In another study, total intestinal CYP3A protein levels were not changed after *in vivo* 1,25-D3 treatment, although *Cyp3a9* mRNA levels were increased by 2-fold and *Cyp3a1* mRNA levels remained unchanged³⁷. As the antibodies to rat CYP3A were unable to distinguish between different isoforms, and the substrate reactions are not specific enough, the evaluation of the change in each CYP3A isoform was conducted more on transcriptional level than expressional or functional levels. Therefore, novel biochemical technologies and animal models are needed to help solve this problem and investigate more deeply into the interaction between VDR and rat CYP3As. Such work will also provide clues for the understanding of human CYP3A regulation and species discrepancies¹⁰⁹.

5. Conclusions

The up-regulatory effects of activated VDR on human CYP3A4 are clearly indicated in *in vitro* and *ex vivo* experiments, and the molecular mechanism is well elucidated. However, the clinical significance of related VDR polymorphisms and/or VDR-mediated CYP3A4 induction remains to be established. Mice and rats are two kinds of commonly used rodent animal models, in which the organ-specific and isoform-specific CYP3A induction by VDR ligands is also observed. It is noteworthy that most studies only focus on the mRNA level changes of CYP3As, but pay less attention to the changes of the relevant protein levels or metabolic activities, which might influence the pharmacokinetic profiles of CYP3A substrates. In particular, more *in vivo* evidence could be provided on VDR in the induction of CYP3A based on the *Vdr* KO mouse or rat models. Despite species discrepancies, the results from mice or rat experiments help to understand better the less focused pathway of CYP3A transcriptional regulation by VDR.

As compared with the broad spectrum of chemicals known to serve as the ligands for PXR and CAR, the ligands of VDR are previously restricted to VD₃ as well as its hydroxylated metabolites and the secondary bile acid LCA. Recently, the VDR-binding capacities of more compounds have been discovered, which show both nutritional and pharmacological significance. Although the affinities of these compounds towards VDR are much weaker than those of the natural ligands, these substances could be massively absorbed from foods and high local concentrations might be effective for VDR agonism. As VD₃ is an important nutrient and an endogenous chemical, the interplay between VD₃ and CYP3A4 should be a special focus, particularly under many pathological conditions and in chemotherapy.

Acknowledgments

This work was supported in part by grants from the National Natural Science Foundation of China (No. 81773808), and the Science and Technology Commission of Shanghai Municipality (Nos. 17140901000, 17140901001 and 18430760400, China).

References

- Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. *Physiol Rev* 2016;**96**:365–408.
- Haussler MR, Whitfield GK, Kaneko I, Haussler CA, Hsieh D, Hsieh JC, et al. Molecular mechanisms of vitamin D action. *Calcif Tissue Int* 2013;**92**:77–98.
- Tebben PJ, Singh RJ, Kumar R. Vitamin D-mediated hypercalcemia: mechanisms, diagnosis, and treatment. *Endocr Rev* 2016;**37**:521–47.
- Suda T, Masuyama R, Bouillon R, Carmeliet G. Physiological functions of vitamin D: what we have learned from global and conditional VDR knock-out mouse studies. *Curr Opin Pharmacol* 2015;**22**:87–99.
- Girgis CM, Baldock PA, Downes M. Vitamin D, muscle and bone: integrating effects in development, aging and injury. *Mol Cell Endocrinol* 2015;**410**:3–10.
- Dakshinamurti K. Vitamins and their derivatives in the prevention and treatment of metabolic syndrome diseases (diabetes). *Can J Physiol Pharmacol* 2015;**93**:355–62.
- Li YX, Zhou L. Vitamin D deficiency, obesity and diabetes. *Cell Mol Biol (Noisy-le-grand)* 2015;**61**:35–8.
- de Sa Del Fiol F, Barberato-Filho S, Lopes LC, de Cassia Bergamaschi C. Vitamin D and respiratory infections. *J Infect Dev Ctries* 2015;**9**:355–61.
- Mozos I, Marginean O. Links between vitamin D deficiency and cardiovascular diseases. *Biomed Res Int* 2015;**2015**:109275.
- Zhang L, Wang S, Che X, Li X. Vitamin D and lung cancer risk: a comprehensive review and meta-analysis. *Cell Physiol Biochem* 2015;**36**:299–305.
- Dou R, Ng K, Giovannucci EL, Manson JE, Qian ZR, Ogino S. Vitamin D and colorectal cancer: molecular, epidemiological and clinical evidence. *Br J Nutr* 2016;**115**:1643–60.
- Burton JM, Costello FE. Vitamin D in multiple sclerosis and central nervous system demyelinating disease—a review. *J Neuroophthalmol* 2015;**35**:194–200.
- Wood JM, Gupta S. Vitamin D and neurocognitive disorder due to Alzheimer's disease: a review of the literature. *Ann Clin Psychiatry* 2015;**27**:e1–7.
- Wang P, Qin X, Liu M, Wang X. The burgeoning role of cytochrome P450-mediated vitamin D metabolites against colorectal cancer. *Pharmacol Res* 2018;**133**:9–20.
- Cecchin E, De Mattia E, Toffoli G. Nuclear receptors and drug metabolism for the personalization of cancer therapy. *Expert Opin Drug Metab Toxicol* 2016;**12**:291–306.
- Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacol Ther* 2013;**138**:103–41.
- Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. *Arch Toxicol* 2008;**82**:667–715.
- Timsit YE, Negishi M. CAR and PXR: the xenobiotic-sensing receptors. *Steroids* 2007;**72**:231–46.
- Wang Z, Schuetz EG, Xu Y, Thummel KE. Interplay between vitamin D and the drug metabolizing enzyme CYP3A4. *J Steroid Biochem Mol Biol* 2013;**136**:54–8.
- Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Watkins PB. Induction of CYP3A4 by 1 α ,25-dihydroxyvitamin D₃ is human cell line-specific and is unlikely to involve pregnane X receptor. *Drug Metab Dispos* 2001;**29**:1446–53.
- Harmsen S, Koster AS, Beijnen JH, Schellens JH, Meijerman I. Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction. *Drug Metab Dispos* 2008;**36**:1166–71.
- Jurutka PW, Thompson PD, Whitfield GK, Eichhorst KR, Hall N, Dominguez CE, et al. Molecular and functional comparison of 1,25-dihydroxyvitamin D₃ and the novel vitamin D receptor ligand, lithocholic acid, in activating transcription of cytochrome P450 3A4. *J Cell Biochem* 2005;**94**:917–43.
- Matsubara T, Yoshinari K, Aoyama K, Sugawara M, Sekiya Y, Nagata K, et al. Role of vitamin D receptor in the lithocholic acid-mediated CYP3A induction *in vitro* and *in vivo*. *Drug Metab Dispos* 2008;**36**:2058–63.
- Thummel KE, Brimer C, Yasuda K, Thottassery J, Senn T, Lin Y, et al. Transcriptional control of intestinal cytochrome P-4503A by 1 α ,25-dihydroxy vitamin D₃. *Mol Pharmacol* 2001;**60**:1399–406.
- Fukumori S, Murata T, Taguchi M, Hashimoto Y. Rapid and drastic induction of CYP3A4 mRNA expression via vitamin D receptor in human intestinal LS180 cells. *Drug Metab Pharmacokinet* 2007;**22**:377–81.
- Thompson PD, Jurutka PW, Whitfield GK, Myskowski SM, Eichhorst KR, Dominguez CE, et al. Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. *Biochem Biophys Res Commun* 2002;**299**:730–8.
- Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, Watkins PB. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1 α ,25-dihydroxyvitamin D₃. *Mol Pharmacol* 1997;**51**:741–54.
- Maguire O, Pollock C, Martin P, Owen A, Smyth T, Doherty D, et al. Regulation of CYP3A4 and CYP3A5 expression and modulation of "intracrine" metabolism of androgens in prostate cells by liganded vitamin D receptor. *Mol Cell Endocrinol* 2012;**364**:54–64.
- Doherty D, Dvorkin SA, Rodriguez EP, Thompson PD. Vitamin D receptor agonist EB1089 is a potent regulator of prostatic "intracrine" metabolism. *Prostate* 2014;**74**:273–85.
- Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, et al. Vitamin D receptor as an intestinal bile acid sensor. *Science* 2002;**296**:1313–6.
- Wang K, Chen S, Xie W, Wan YJ. Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway. *Biochem Pharmacol* 2008;**75**:2204–13.
- Chow EC, Maeng HJ, Liu S, Khan AA, Groothuis GM, Pang KS. 1 α ,25-Dihydroxyvitamin D₃ triggered vitamin D receptor and farnesoid X receptor-like effects in rat intestine and liver *in vivo*. *Bio-pharm Drug Dispos* 2009;**30**:457–75.
- Khan AA, Dragt BS, Porte RJ, Groothuis GM. Regulation of VDR expression in rat and human intestine and liver—consequences for CYP3A expression. *Toxicol In Vitro* 2010;**24**:822–9.
- Khan AA, Chow EC, Porte RJ, Pang KS, Groothuis GM. The role of lithocholic acid in the regulation of bile acid detoxication, synthesis, and transport proteins in rat and human intestine and liver slices. *Toxicol In Vitro* 2011;**25**:80–90.
- Khan AA, Chow EC, van Loenen-Weemaes AM, Porte RJ, Pang KS, Groothuis GM. Comparison of effects of VDR versus PXR, FXR and GR ligands on the regulation of CYP3A isozymes in rat and human intestine and liver. *Eur J Pharm Sci* 2009;**37**:115–25.
- Chow EC, Sun H, Khan AA, Groothuis GM, Pang KS. Effects of 1 α ,25-dihydroxyvitamin D₃ on transporters and enzymes of the rat intestine and kidney *in vivo*. *Biopharm Drug Dispos* 2010;**31**:91–108.
- Chow EC, Sondervan M, Jin C, Groothuis GM, Pang KS. Comparative effects of doxercalciferol (1 α -hydroxyvitamin D₂) versus calcitriol (1 α ,25-dihydroxyvitamin D₃) on the expression of transporters and enzymes in the rat *in vivo*. *J Pharm Sci* 2011;**100**:1594–604.
- Lindh JD, Bjorkhem-Bergman L, Eliasson E. Vitamin D and drug-metabolising enzymes. *Photochem Photobiol Sci* 2012;**11**:1797–801.

39. Slominski AT, Kim TK, Hobrath JV, Oak ASW, Tang EKY, Tieu EW, et al. Endogenously produced nonclassical vitamin D hydroxymetabolites act as “biased” agonists on VDR and inverse agonists on ROR α and ROR γ . *J Steroid Biochem Mol Biol* 2017;**173**:42–56.
40. Hashizume T, Xu Y, Mohutsky MA, Alberts J, Hadden C, Kalthorn TF, et al. Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1 α ,25-dihydroxyvitamin D₃ conjugation. *Biochem Pharmacol* 2008;**75**:1240–50.
41. Wang Z, Lin YS, Zheng XE, Senn T, Hashizume T, Scian M, et al. An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway. *Mol Pharmacol* 2012;**81**:498–509.
42. Cheng CY, Slominski AT, Tuckey RC. Hydroxylation of 20-hydroxyvitamin D₃ by human CYP3A4. *J Steroid Biochem Mol Biol* 2016;**159**:131–41.
43. Deb S, Pandey M, Adomat H, Guns ES. Cytochrome P450 3A-mediated microsomal biotransformation of 1 α ,25-dihydroxyvitamin D₃ in mouse and human liver: drug-related induction and inhibition of catabolism. *Drug Metab Dispos* 2012;**40**:907–18.
44. Xu Y, Hashizume T, Shuhart MC, Davis CL, Nelson WL, Sakaki T, et al. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1 α ,25-dihydroxyvitamin D₃: implications for drug-induced osteomalacia. *Mol Pharmacol* 2006;**69**:56–65.
45. Zheng XE, Wang Z, Liao MZ, Lin YS, Shuhart MC, Schuetz EG, et al. Human PXR-mediated induction of intestinal CYP3A4 attenuates 1 α ,25-dihydroxyvitamin D₃ function in human colon adenocarcinoma LS180 cells. *Biochem Pharmacol* 2012;**84**:391–401.
46. Deb S, Chin MY, Adomat H, Guns ES. Ginsenoside-mediated blockade of 1 α ,25-dihydroxyvitamin D₃ inactivation in human liver and intestine *in vitro*. *J Steroid Biochem Mol Biol* 2014;**141**:94–103.
47. Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. The expression of nuclear and steroid receptors. *Biochim Biophys Acta* 2003;**1619**:243–53.
48. Martinez-Jimenez CP, Jover R, Donato MT, Castell JV, Gomez-Lechon MJ. Transcriptional regulation and expression of CYP3A4 in hepatocytes. *Curr Drug Metab* 2007;**8**:185–94.
49. Ihunnah CA, Jiang M, Xie W. Nuclear receptor PXR, transcriptional circuits and metabolic relevance. *Biochim Biophys Acta* 2011;**1812**:956–63.
50. Lee SY, Lee JY, Kim YM, Kim SK, Oh SJ. Expression of hepatic cytochrome P450s and UDP-glucuronosyltransferases in PXR and CAR double humanized mice treated with rifampicin. *Toxicol Lett* 2015;**235**:107–15.
51. Moore JT, Klierer SA. Use of the nuclear receptor PXR to predict drug interactions. *Toxicology* 2000;**153**:1–10.
52. Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, et al. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. *J Biol Chem* 2003;**278**:17277–83.
53. Moore LB, Parks DJ, Jones SA, Bledsoe RK, Conslor TG, Stimmel JB, et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. *J Biol Chem* 2000;**275**:15122–7.
54. Healan-Greenberg C, Waring JF, Kempf DJ, Blomme EA, Tirona RG, Kim RB. A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. *Drug Metab Dispos* 2008;**36**:500–7.
55. Krausova L, Stejskalova L, Wang H, Vrzal R, Dvorak Z, Mani S, et al. Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene. *Biochem Pharmacol* 2011;**82**:1771–80.
56. Wang H, Negishi M. Transcriptional regulation of cytochrome p450 2B genes by nuclear receptors. *Curr Drug Metab* 2003;**4**:515–25.
57. Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, Negishi M. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. *J Biol Chem* 1999;**274**:6043–6.
58. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, Klierer SA. Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. *Mol Pharmacol* 2002;**62**:638–46.
59. Wolf G. Intestinal bile acids can bind to and activate the vitamin D receptor. *Nutr Rev* 2002;**60**:281–3.
60. Heldin CH, Lu B, Evans R, Gutkind JS. Signals and receptors. *Cold Spring Harb Perspect Biol* 2016;**8**:a005900.
61. Pavek P, Pospechova K, Svecova L, Syrova Z, Stejskalova L, Blazkova J, et al. Intestinal cell-specific vitamin D receptor (VDR)-mediated transcriptional regulation of CYP3A4 gene. *Biochem Pharmacol* 2010;**79**:277–87.
62. Hara H, Yasunami Y, Adachi T. Loss of CYP3A7 gene induction by 1,25-dihydroxyvitamin D₃ is caused by less binding of VDR to the proximal ER6 in CYP3A7 gene. *Biochem Biophys Res Commun* 2004;**321**:909–15.
63. Tirona RG, Lee W, Leake BF, Lan LB, Cline CB, Lamba V, et al. The orphan nuclear receptor HNF4 α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. *Nat Med* 2003;**9**:220–4.
64. Raunio H, Hakkola J, Pelkonen O. Regulation of CYP3A genes in the human respiratory tract. *Chem Biol Interact* 2005;**151**:53–62.
65. Daly AK. Significance of the minor cytochrome P450 3A isoforms. *Clin Pharmacokinet* 2006;**45**:13–31.
66. Nem D, Baranyai D, Qiu H, Godtel-Armbrust U, Nestler S, Wojnowski L. Pregnane X receptor and yin yang 1 contribute to the differential tissue expression and induction of CYP3A5 and CYP3A4. *PLoS One* 2012;**7**:e30895.
67. Burk O, Tegude H, Koch I, Hustert E, Wolbold R, Glaeser H, et al. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. *J Biol Chem* 2002;**277**:24280–8.
68. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. *Pharmacogenetics* 2001;**11**:111–21.
69. Agarwal V, Kommaddi RP, Valli K, Ryder D, Hyde TM, Kleinman JE, et al. Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite. *PLoS One* 2008;**3**:e2337.
70. Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. *Mol Pharmacol* 2001;**59**:386–92.
71. Krusekopf S, Roots I, Kleeberg U. Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. *Eur J Pharmacol* 2003;**466**:7–12.
72. Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. *J Biol Chem* 2002;**277**:25125–32.
73. Qin X, Liu M, Wang X. New insights into the androgen biotransformation in prostate cancer: a regulatory network among androgen, androgen receptors and UGTs. *Pharmacol Res* 2016;**106**:114–22.
74. Ishizawa M, Ogura M, Kato S, Makishima M. Impairment of bilirubin clearance and intestinal interleukin-6 expression in bile duct-ligated vitamin D receptor null mice. *PLoS One* 2012;**7**:e51664.
75. Fan J, Maeng HJ, Du Y, Kwan D, Pang KS. Transport of 5,5-diphenylbarbituric acid and its precursors and their effect on P-gp, MRP2 and CYP3A4 in Caco-2 and LS180 cells. *Eur J Pharm Sci* 2011;**42**:19–29.
76. Eloranta JJ, Hiller C, Juttner M, Kullak-Ublick GA. The *SLCO1A2* gene, encoding human organic anion-transporting polypeptide 1A2, is transactivated by the vitamin D receptor. *Mol Pharmacol* 2012;**82**:37–46.
77. Hara H, Yasunami Y, Adachi T. Alteration of cellular phosphorylation state affects vitamin D receptor-mediated CYP3A4 mRNA induction in Caco-2 cells. *Biochem Biophys Res Commun* 2002;**296**:182–8.
78. Yasunami Y, Hara H, Iwamura T, Kataoka T, Adachi T. C-jun N-terminal kinase modulates 1,25-dihydroxyvitamin D₃-induced cytochrome P450 3A4 gene expression. *Drug Metab Dispos* 2004;**32**:685–8.

79. Elizondo G, Medina-Diaz IM. Induction of CYP3A4 by $1\alpha,25$ -dihydroxyvitamin D3 in HepG2 cells. *Life Sci* 2003;**73**:141–9.
80. Hines RN. Ontogeny of human hepatic cytochromes P450. *J Biochem Mol Toxicol* 2007;**21**:169–75.
81. Betts S, Bjorkhem-Bergman L, Rane A, Ekstrom L. Expression of CYP3A4 and CYP3A7 in human foetal tissues and its correlation with nuclear receptors. *Basic Clin Pharmacol Toxicol* 2015;**117**:261–6.
82. Theodoropoulos C, Demers C, Delvin E, Menard D, Gascon-Barre M. Calcitriol regulates the expression of the genes encoding the three key vitamin D3 hydroxylases and the drug-metabolizing enzyme CYP3A4 in the human fetal intestine. *Clin Endocrinol (Oxf)* 2003;**58**:489–99.
83. von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. *Clin Pharmacol Ther* 2004;**75**:172–83.
84. Lindh JD, Andersson ML, Eliasson E, Bjorkhem-Bergman L. Seasonal variation in blood drug concentrations and a potential relationship to vitamin D. *Drug Metab Dispos* 2011;**39**:933–7.
85. Tsujimoto M, Nagano Y, Hosoda S, Shiraishi A, Miyoshi A, Hiraoka S, et al. Effects of decreased vitamin D and accumulated uremic toxin on human CYP3A4 activity in patients with end-stage renal disease. *Toxins (Basel)* 2013;**5**:1475–85.
86. Mannheimer B, Wagner H, Ostenson CG, Diczfalusy U. No impact of vitamin D on the CYP3A biomarker 4β -hydroxycholesterol in patients with abnormal glucose regulation. *PLoS One* 2015;**10**:e0121984.
87. Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. *Clin Pharmacol Ther* 2009;**85**:198–203.
88. Kollitz EM, Zhang G, Hawkins MB, Whitfield GK, Reif DM, Kullman SW. Evolutionary and functional diversification of the vitamin D receptor–lithocholic acid partnership. *PLoS One* 2016;**11**:e0168278.
89. Zhou H, Hylemon PB. Bile acids are nutrient signaling hormones. *Steroids* 2014;**86**:62–8.
90. Bodin K, Lindbom U, Diczfalusy U. Novel pathways of bile acid metabolism involving CYP3A4. *Biochim Biophys Acta* 2005;**1687**:84–93.
91. Maestro MA, Molnar F, Mourino A, Carlberg C. Vitamin D receptor 2016: novel ligands and structural insights. *Expert Opin Ther Pat* 2016;**26**:1291–306.
92. Bartik L, Whitfield GK, Kaczmarek M, Lowmiller CL, Moffet EW, Furrick JK, et al. Curcumin: a novel nutritionally derived ligand of the vitamin D receptor with implications for colon cancer chemoprevention. *J Nutr Biochem* 2010;**21**:1153–61.
93. Chae YJ, Cho KH, Yoon IS, Noh CK, Lee HJ, Park Y, et al. Vitamin D receptor-mediated upregulation of CYP3A4 and MDR1 by quercetin in Caco-2 cells. *Planta Med* 2016;**82**:121–30.
94. Li L, Stanton JD, Tolson AH, Luo Y, Wang H. Bioactive terpenoids and flavonoids from *Ginkgo biloba* extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. *Pharm Res* 2009;**26**:872–82.
95. Price DK, Franks ME, Figg WD. Genetic variations in the vitamin D receptor, androgen receptor and enzymes that regulate androgen metabolism. *J Urol* 2004;**171**:S45–9. discussion S49.
96. Nylen H, Bjorkhem-Bergman L, Ekstrom L, Roh HK, Bertilsson L, Eliasson E, et al. Plasma levels of 25-hydroxyvitamin D3 and *in vivo* markers of cytochrome P450 3A activity in Swedes and Koreans: effects of a genetic polymorphism and oral contraceptives. *Basic Clin Pharmacol Toxicol* 2014;**115**:366–71.
97. Thirumaran RK, Lamba JK, Kim RB, Urquhart BL, Gregor JC, Chande N, et al. Intestinal CYP3A4 and midazolam disposition *in vivo* associate with VDR polymorphisms and show seasonal variation. *Biochem Pharmacol* 2012;**84**:104–12.
98. Robien K, Butler LM, Wang R, Beckman KB, Walek D, Koh WP, et al. Genetic and environmental predictors of serum 25-hydroxyvitamin D concentrations among middle-aged and elderly Chinese in Singapore. *Br J Nutr* 2013;**109**:493–502.
99. Komura H, Iwaki M. *In vitro* and *in vivo* small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences. *Drug Metab Rev* 2011;**43**:476–98.
100. Hagemeyer CE, Burck C, Schwab R, Knoth R, Meyer RP. 7-Benzyloxyresorufin-*O*-dealkylase activity as a marker for measuring cytochrome P450 CYP3A induction in mouse liver. *Anal Biochem* 2010;**398**:104–11.
101. Meyer RP, Gehlhaus M, Schwab R, Burck C, Knoth R, Hagemeyer CE. Concordant up-regulation of cytochrome P450 Cyp3a11, testosterone oxidation and androgen receptor expression in mouse brain after xenobiotic treatment. *J Neurochem* 2009;**109**:670–81.
102. Gascon-Barre M, Demers C, Mirshahi A, Neron S, Zalzal S, Nanci A. The normal liver harbors the vitamin D nuclear receptor in non-parenchymal and biliary epithelial cells. *Hepatology* 2003;**37**:1034–42.
103. Zhou C, Assem M, Tay JC, Watkins PB, Blumberg B, Schuetz EG, et al. Steroid and xenobiotic receptor and vitamin D receptor cross-talk mediates CYP24 expression and drug-induced osteomalacia. *J Clin Invest* 2006;**116**:1703–12.
104. Cheng J, Fang ZZ, Kim JH, Krausz KW, Tanaka N, Chiang JY, et al. Intestinal CYP3A4 protects against lithocholic acid-induced hepatotoxicity in intestine-specific VDR-deficient mice. *J Lipid Res* 2014;**55**:455–65.
105. Xu Y, Iwanaga K, Zhou C, Cheesman MJ, Farin F, Thummel KE. Selective induction of intestinal CYP3A23 by $1\alpha,25$ -dihydroxyvitamin D3 in rats. *Biochem Pharmacol* 2006;**72**:385–92.
106. Durk MR, Fan J, Sun H, Yang Y, Pang H, Pang KS, et al. Vitamin D receptor activation induces P-glycoprotein and increases brain efflux of quinidine: an intracerebral microdialysis study in conscious rats. *Pharm Res* 2015;**32**:1128–40.
107. Zierold C, Mings JA, Deluca HF. 19Nor-1,25-dihydroxyvitamin D2 specifically induces CYP3A9 in rat intestine more strongly than 1,25-dihydroxyvitamin D3 *in vivo* and *in vitro*. *Mol Pharmacol* 2006;**69**:1740–7.
108. Matsubara T, Kim HJ, Miyata M, Shimada M, Nagata K, Yamazoe Y. Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat. *J Pharmacol Exp Ther* 2004;**309**:1282–90.
109. Lu J, Shao Y, Qin X, Liu D, Chen A, Li D, et al. CRISPR knockout rat cytochrome P450 3A1/2 model for advancing drug metabolism and pharmacokinetics research. *Sci Rep* 2017;**7**:42922.